Data Packages, Inspections & Delayed Submissions: EMA Addresses Frequent Questions About Raw Data Pilot

Is it permissible to use data packages prepared for other international regulators? This is among the many questions the European Medicines Agency has addressed about its new pilot on analyzing raw data from clinical trials.

Close up.employees discuss financial data. photo with copy space
The EMA is exploring if analyzing raw data is beneficial • Source: Alamy

Drug companies taking part in a new pilot that the European Medicines Agency launched to assess whether the analysis of raw data from clinical trials can help it improve its medicines evaluation process might be able to use data packages prepared for other international regulators.

In addition, once companies have confirmed their intention to participate in the voluntary initiative, under which they must submit their...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

More from Pink Sheet